Sign up to save your podcasts
Or
Share Managing comorbidities in diabetes: Obesity
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing comorbidities in diabetes: Obesity
As metabolic diseases, obesity and diabetes commonly present alongside one another. However, how should these conditions be managed alongside one another? What treatments are available and recommended for obesity, and how should these be considered alongside type 2 diabetes?
Joining us this week to answer this very question is Professor Carel le Roux, of University College Dublin.
References:
- Behary P, et al. Diabetes Care 2019, 42 (8) 1446-1453
- Daousi C, et al. Postgrad Med J. 2006 82(966):280-4.
- le Roux CW, et al. Obes Surg. 2020 Aug 26.
- Ling C, Rönn T, Cell Metab. 2019;29(5):1028-1044.
- Malone JI, Hansen B. Pediatr Diabetes. 2019 20(1):5-9.
- Nowakowska M, et al. BMC Med. 2019;17(1):145.
- Yumuk V, et al. Obes Facts. 2015;8:402-424
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education
View all episodes
By Liberum IME
5
11 ratings
As metabolic diseases, obesity and diabetes commonly present alongside one another. However, how should these conditions be managed alongside one another? What treatments are available and recommended for obesity, and how should these be considered alongside type 2 diabetes?
Joining us this week to answer this very question is Professor Carel le Roux, of University College Dublin.
References:
- Behary P, et al. Diabetes Care 2019, 42 (8) 1446-1453
- Daousi C, et al. Postgrad Med J. 2006 82(966):280-4.
- le Roux CW, et al. Obes Surg. 2020 Aug 26.
- Ling C, Rönn T, Cell Metab. 2019;29(5):1028-1044.
- Malone JI, Hansen B. Pediatr Diabetes. 2019 20(1):5-9.
- Nowakowska M, et al. BMC Med. 2019;17(1):145.
- Yumuk V, et al. Obes Facts. 2015;8:402-424
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education